Pluri Inc(PLUR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.45 | Insider Own | 33.96% | Shs Outstand | 10.8M | Perf Week | 18.81% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | 24.15% | Shs Float | 8.3M | Perf Month | 20% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 10.83% | Short Float | 0.25% | Perf Quarter | -22.58% |
| Income | -0.02B | P/S | 14.84 | EPS this Y | - | Inst Trans | -0.02% | Short Ratio | 0.63 | Perf Half Y | -65.53% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -74.95% | Short Interest | 0.02M | Perf YTD | -59.87% |
| Book/sh | -2.13 | P/C | 1.93 | EPS past 3/5Y | 26.6% 29.65% | ROE | - | 52W High | -75.33% ($4.86) | Perf Year | -68.09% |
| Cash/sh | 0.62 | P/FCF | - | Sales past 3/5Y | 52.41% - | ROIC | - | 52W Low | 41.18% ($0.85) | Perf 3Y | -68.75% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 30.12% | Gross Margin | -5.71% | Volatility(W/M) | 23.3% 12.27% | Perf 5Y | -94.34% |
| Dividend TTM | - | EV/Sales | 46.87 | Sales Y/Y TTM | -23.95% | Oper. Margin | -2454.53% | ATR (14) | 0.15 | Perf 10Y | -99.06% |
| Dividend Ex-Date | - | Quick Ratio | 0.27 | EPS Q/Q | 43.56% | Profit Margin | -2344.59% | RSI (14) | 59.35 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.27 | Sales Q/Q | -15.83% | SMA20 | 18.35% ($1.01) | Beta | 0.69 | Target Price | $12 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | 2.25% ($1.17) | Rel Volume | 1.15 | Prev Close | $1.23 |
| Employees | 92 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -49.8% ($2.39) | Avg Volume(3M) | 0.03M | Price | $1.2 |
| IPO | 2003/4/16 | Option/Short | No/Yes | Trades | 148 | Volume | 38,527 | Change | -2.44% |
Pluristem () is a biotech company headquartered in Haifa, Israel. Built around its proprietary 3D cell mass-production platform, it operates across regenerative medicine, cell agriculture, food tech, and CDMO (contract development and manufacturing) services. The company is developing its PLX series of cell therapy candidates targeting conditions such as peripheral artery disease and hematopoietic recovery, while also extending its platform into the food sector with cultivated meat and cell-based coffee.
Over the past 1 year, on the lower side
75% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
PLUR has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,484. Peers typically go for $1,089. Compared with its own 2-year average, it is 73% pricier now.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 10.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DFIS Dimensional International Small Cap ETF <0.01% It ranks #476 of 594 in the industry
Based on market cap of $15M.
FAQ
What kind of company is PLUR?
PLUR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PLUR?
The market cap of PLUR is approximately $15M, ranking 5,303 within its sector.
What is the 52-week high and low for PLUR?
PLUR has recorded a 52-week high of $4.86 and a low of $0.85.
